Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2

A Case Series Quantitative Systematic Review

Raúl Bustos B, MD,* Juan Camilo Jaramillo-Bustamante, MD,‡‡ Pablo Vasquez-Hoyos, MD, MSc,§§¶|| Pablo Cruces, MD,### and Franco Díaz, MD, MBA*****§§§§

BACKGROUND

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has quickly spread worldwide, from the initial outbreak in Wuhan, China, to Southeast Asia and Oceania, Europe, and then the Americas.1–3 During April 2020 and the following months, several small case series were published, describing children with an abnormal systemic inflammatory response, temporally associated with SARS-CoV-2.4–22 These children required hospitalization and frequently presented a life-threatening disease requiring pediatric intensive care unit (PICU) admission. This syndrome shares characteristics with other pediatric inflammatory conditions, including Kawasaki disease (KD), staphylococcal and streptococcal toxic shock syndromes, sepsis, and macrophage activation syndrome. Authors are trying to classify these syndromes according to the predominant signs and symptoms, leading to confusing terminology, not very useful to the clinician at the bedside.23–26 This syndrome has been called by many names and acronyms, like PIMS-TS (pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2), MIS-C (multisystem inflammatory syndrome in children), hyperinflammatory shock, cytokine storm, among others.

We present a systematic review of the cases of inflammatory syndromes associated with SARS-CoV-2 infection published until July 1, 2020. For this review, we will ascribe to PIMS-TS denomination.

METHODS

We evaluated relevant studies in PubMed, LILACS, and Embase, published between May 1 to July 1, 2020, using combinations of the terms “pediatrics,” “coronavirus,” “COVID-19,” “SARS-CoV-2,” “pediatric intensive care,” “pediatric inflammatory multisystem syndrome,” “Kawasaki disease,” and “hyperinflammatory Kawasaki · PIMS-TS · MIS-C · COVID-19 · SARS-CoV-2.” We retrieved studies with at least 3 patients, and pediatric age was considered younger than 21 years. We excluded studies that had duplicate patients from other reports. Quality of measures was assessed by the tool developed by Murad et al.27 Data extraction was performed by 2 independent reviewers (R.B.B. and J.C.J.-B.). Data were initially described by study using the presented measurement of distribution on the original paper. A meta-analysis was carried out if the variable of interest was present in more than 50% of studies. Detailed method for quantitative meta-analysis is available in supplementary file 1, http://links.lww.com/PEC/A653.

RESULTS

We found 184 potentially relevant articles. Eleven case series were selected for this review (supplementary file 2, http://links.lww.com/PEC/A657). The quality score of the included studies is shown in supplementary file 3, http://links.lww.com/PEC/A655. Supplementary files 4 and 5, http://links.lww.com/PEC/A656 show detailed clinical and laboratory data of the analyzed studies. Reported cases came from 196 centers describing a total of 468 children. Clinical characteristics are shown in Table 1. The average age was 9.2 years (95% confidence interval [CI], 8.5–9.9), and all patients were febrile at presentation. Rash was reported in 58% (95% CI, 52%–63%), conjunctivitis in 56% (95% CI, 42%–69%), and shock in 76% (95% CI, 55%–93%). A positive test for SARS CoV-2 was available in reverse transcription polymerase chain reaction (RT-PCR) 38% (95% CI, 29%–46%), serology 68% (95% CI, 50%–84%), and a known positive contact in
soactive drugs (Fig. 1B), and 59% (95% CI, 40%–66%) required renal replacement therapy. Eighty-one children (17.6%) were still hospitalized at the time the case series were reported.


discussion

In this systematic review of PIMS-TS cases in the literature, we found a great deal of heterogeneity. The cases reported are numerous, from several centers, but there is no standardized description of the variables of interest. We analyzed 11 case series, including 468 children from 196 centers. Instead of listing studies and patients, we performed a quantitative analysis according to the weighed cases of the studies. Our main findings can be summarized as follows:

1) We were able to define the most frequent clinical characteristics of patients: previously healthy school-aged children, presenting with persistent fever and gastrointestinal symptoms.
2) Clinical syndromes like myocarditis and KD were present only one third of cases each one.
3) High level of care (PICU) was very frequent, although LOS was less than 1 week, and mortality was very low.
4) Most patients received immunoglobulin or steroids, although the level of evidence for that treatment is low.

Given the current hypotheses of the physiopathology of PIMS-TS, viral infection versus a postinfectious disease, it is important to note that RT-PCR was positive in 38% and serology in 66% of cases. An alternative hypothesis might be that these symptoms and clinical syndromes are also present in non-SARS-CoV-2 coronaviruses. For instance, there are some cases of myocarditis and KD associated with human coronavirus exposure. Thus, the clusters of PIMS-TS observed may be secondary to massive exposure to a trigger in a susceptible population, but not specifically to SARS-CoV-2. Most of the patients were previously healthy.

TABLE 1. Overall Pooled Effects of Demographics and Clinical Characteristics of 486 Children With PIMS-TS

| Demographics | Studies, n/N | Cases, n/N | Pooled Effects* (95% CI, I²) |
|--------------|-------------|------------|-----------------------------|
| Age, y       | 11/11       | 468/468    | 9.2 (8.5–9.9, 53%)          |
| Male sex     | 11/11       | 263/468    | 54% (48%–61%, 28%)         |
| Previously healthy | 10/11 | 337/453    | 78% (66%–88%, 81%)        |
| Obesity      | 6/11        | 90/360     | 24% (16%–33%, 52%)        |
| Any respiratory comorbidity | 9/11 | 56/443     | 6% (2%–12%, 58%)         |

| Known contact | 9/11        | 151/405    | 29% (14%–47%, 89%)        |
| Positive RT-PCR | 11/11 | 188/468    | 38% (29%–46%, 56%)       |
| Positive serology | SARS-CoV-2 | 11/11       | 269/468     | 68% (50%–84%, 91%)       |

| Clinical | Studies, n/N | Cases, n/N | Pooled Effects* (95% CI, I²) |
|----------|-------------|------------|-----------------------------|
| Any GI symptom | 11/11 | 468/468    | 85% (74%–94%, 81%)         |
| Shock criteria | 10/11 | 163/218    | 76% (55%–93%, 91%)        |
| Rash      | 10/11      | 268/453    | 58% (52%–63%, 10%)       |
| Conjunctivitis | 9/11 | 231/416    | 56% (42%–69%, 78%)       |
| Any respiratory symptoms | 6/11 | 81/216     | 37% (19%–56%, 80%)       |
| Neurological symptoms | 11/11 | 117/468    | 33% (18%–51%, 91%)       |
| AKI       | 7/11       | 69/473     | 33% (14%–55%, 93%)       |
| Myocarditis criteria | 8/11 | 95/242     | 29% (3%–66%, 96%)       |
| KD criteria | 9/11   | 149/428    | 26% (13%–40%, 85%)      |

*Variable must be present in more than 50% of studies. Standardized means by transformation approach. For pooled proportions, we used the metaprop module.

AKI indicates acute kidney injury; GI, gastrointestinal; PIMS-TS, pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2.

Children With PIMS-TS

| Laboratory Test | Studies, n/N | Cases, n/N | Pooled Effects* (95% CI, I²) |
|-----------------|-------------|------------|-----------------------------|
| C-reactive protein | 11/11 | 468/468    | 226 (206–246, 84%)       |
| Procalcitonin, ng/mL | 7/11 | 199/199    | 58 (34–83, 70%)        |
| Ferritin, ng/mL | 8/11 | 392/392    | 727 (593–860, 60%)      |
| D-dimer, ng/mL | 9/11 | 432/432    | 4230 (2311–6148, 41%)   |
| Lymphocyte count, ×10^9/L | 8/11 | 232/232    | 2320 (1.64–1.50, 92%)   |
| Platelet count, ×10^9/L | 8/11 | 413/413    | 207 (135–279, 98%)      |
| Albumin, g/dL | 7/11 | 410/410    | 2.5 (2.0–2.9, 49%)       |

*Variable must be present in more than 50% of studies. Standardized means by transformation approach. For pooled proportions, we used the metaprop module.
school-aged children. Remarkably, all patients had fever. Gastrointestinal symptoms were frequent, as well as rash and mucositis. Regards laboratory examination, all inflammatory markers were elevated, being the most consistent C-reactive protein. C-reactive protein is very unspecific, but it is disproportionally elevated, approximately 20 times the normal value. Lymphopenia was also commonly found. Cases of PIMS-TS fulfilling criteria for KD and myocarditis were not reported frequently, approximately one-third of cases each. Respiratory and neurological symptoms were usually mild, and acute kidney injury accounted for one third. There was a high number of patients with shock criteria, explaining the frequent requirement of PICU admissions. In our study, less than 50% of children with PIMS-TS had abnormal chest x-ray or CT scan. Left ventricular dysfunction was reported in approximately half on the patients, explaining the high frequency of shock and vasoactive support requirements. Coronary abnormalities were described in one fourth of cases during the acute phase, so we cannot extrapolate our results to mid- and long-term sequelae.

Regarding treatments, most PIMS-TS patients received intravenous immunoglobulin or steroids. Surprisingly, despite the severity of cases, antiviral therapy was very uncommon. Most of the children with PIMS-TS were admitted to PICU and required invasive interventions. However, ECMO and continuous renal replacement therapy were very uncommon. Despite the severity of admission and life support requirements, the overall prognosis of PIMS-TS was good. The average PICU LOS was less than a week, and mortality is very low.

Our study has some limitations. First, there are subtle differences in diagnosis criteria (the Royal College of Paediatrics and Child Health, Centers for Disease Control and Prevention, World Health Organization) that can lead to a bias in the selection of patients in different countries and regions. No specific information was requested to authors, and case-by-case review was not done, contributing to the heterogeneity of parameters reported. Patients described in the analyzed studies were only from Europe and North America. Risk factors to develop PIMS-TS, like socioeconomic deprived or genetically susceptible children, are still not well understood, which make the behavior of the pandemic unpredictable in regions such as Latin America and Africa. Second, many small series were added to build larger cohorts. To avoid duplication of data, case reports and some small series were not included. A large cohort has more power in the analysis, but usually, some specific data are lost. Third, PIMS-TS is a new syndrome, and our understanding is still limited. Many nonepidemiological factors, like disease awareness, media, and academic pressure, and loose criteria for diagnosis may lead to overdiagnosis as pandemic develops. However, we analyzed the quality of the studies with a standardized validated tool.

In summary, PIMS-TS is an infrequent and heterogeneous disease. It can mimic some pediatric inflammatory syndromes, like KD, macrophage activation syndrome, and myocarditis, but only in one third of cases can fulfill strict criteria. Clinical characteristics are very distinctive when compared with pediatric COVID-19 infections, frequently presenting as a severe disease. Given the

![Figure 1](www.pec-online.com)
recent description of PIMS-TS, there are still many questions regards its physiopathology, although, with the current empirical treatment, it has a good prognosis.

REFERENCES

1. WHO. Coronavirus disease (COVID-19) situation report – 198. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200805-covid-19-sitrep-198.pdf?sfvrsn=99d1754_2. Accessed August 8, 2020.

2. Wu Z, McGoogan JM. Characteristics of and important lessons from the 2019 novel coronavirus (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1219–1222.

3. Carenzo L, Costantini E, Greco M, et al. Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy. Anaesthesia. 2020;75:928–934.

4. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395:1607–1608.

5. Latimer G, Corriveau C, DeBiasi RL, et al. Cardiac dysfunction and thrombocytopenia-associated multiple organ failure inflammation phenotype in a severe paediatric case of COVID-19. Lancet Child Adolesc Health. 2020;4:552–554.

6. Wolfler A, Mannarino S, Giacomet V, et al. Acute myocardial injury: a novel clinical pattern in children with COVID-19. Lancet Child Adolesc Health. 2020;4:e26–e27.

7. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771–1778.

8. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children and adolescents. Pediatr Cardiol. 2020;41:1391–1401.

9. Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020;79:1006–1008.

10. Cabrero-Hernández M, García-Salido A, Loez-Gordillo I, et al. Severe SARS-CoV-2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in Spain. Pediatr Infect Dis J. 2020;39:e195–e198.

11. Capone CA, Subramony A, Sweeney T, et al. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection. J Pediatr. 2020;224:141–145.

12. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York state. N Engl J Med. 2020;383:347–358.

13. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334–346.

14. Royal College of Paediatrics and Child Health. RCPh guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Available at: https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf. Accessed July 8, 2020.

15. WHO. Multisystem inflammatory syndrome in children and adolescents temporally associated with COVID-19. Available at: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.

16. Bustos B R. Síndrome inflamatorio multisistémico asociado con SARS-CoV-2 en pediatría. Rev Chil Pediatr. 2020;91:646–647.

17. Murad MH, Sultan S, Haflar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med. 2018;23:60–63.

18. Perez-Toledo M, Faustini SE, Jossi SE, et al. Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with paediatric inflammatory multi-system syndrome. medRxiv. 2020. doi: 10.1101/2020.06.05.20123117. [Epub ahead of print].

19. Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020;20:453–454.

20. Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis. 2005;191:499–502.

21. Russo S, Sasser W, Diaz F, et al. Coronavirus associated fulminant myocarditis successfully treated with intravenous immunoglobulin and extracorporeal membrane oxygenation. Chest. 2014;146:336A.

22. Bonow RO, Fonarow GC, O’Gara PT, et al. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020;5:751–753.

23. Blondiaux E, Parisot P, Redheuil A, et al. Cardiac MRI of children with multisystem inflammatory syndrome (MIS-C) associated with COVID-19: case series. Radiology. 2020;202288.